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Currently, oral infection is the most frequent transmission mechanism of Chagas disease 
in Brazil and others Latin American countries. This transmission pathway presents 
increased mortality rate in the first 2 weeks, which is higher than the calculated mor-
tality after the biting of infected insect vectors. Thus, the oral route of Trypanosoma 
cruzi infection, and the consequences in the host must be taken into account when 
thinking on the mechanisms underlying the natural history of the disease. Distinct 
routes of parasite entry may differentially affect immune circuits, stimulating regional 
immune responses that impact on the overall profile of the host protective immunity. 
Experimental studies related to oral infection usually comprise inoculation in the mouth 
(oral infection, OI) or gavage (gastrointestinal infection, GI), being often considered as 
similar routes of infection. Hence, establishing a relationship between the inoculation site 
(OI or GI) with disease progression and the mounting of T. cruzi-specific regional immune 
responses is an important issue to be considered. Here, we provide a discussion on 
studies performed in OI and GI in experimental models of acute infections, including 
T. cruzi infection.
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iNTRODUCTiON
Chagas disease, or American trypanosomiasis, caused by the hemoflagellate protozoan Trypanosoma 
cruzi, is a tropical neglected illness Trypanosoma cruzi (T. cruzi). Infection was initially enzooty and 
maintained among wild animals and insect vectors of the Reduviidae family. Deforestation in rural 
areas allowed vectors to invade human homes (1, 2).
Chagas disease transmission to humans can be classified in primary (vectorial, blood transfu-
sion, congenital, and orally) and secondary (less frequent, such as laboratory accident, handling of 
infected animals, organ transplantation from infected donors, and hypothetically through sexual) 
routes of T. cruzi infection (3, 4). Different transmission routes present variable incubation period, 
such as oral, 3–22 days; vector feces near the bite, 4–15 days; blood transfusion, 8–120 days; and 
organ transplantation, 23–420 days (5–9). Besides the transmission pathway, mortality rates depend 
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also on the patients’ clinical condition and on the time between 
disease diagnosis and beginning of treatment. Oral transmission 
results in a higher mortality, estimated between 8 and 35%, than 
the classical vector-borne infection (<5–10%) (5, 7–10).
From 1990 to 1993, the Brazilian Health Minister started to 
insert the Notifiable Diseases System of Information-SINAN 
(DATASUS) to control the number of acute cases in the country. 
Although underestimated, from 2002 to 2006 Brazil registered 
2510 cases of acute Chagas disease according to the DATASUS 
system. Number of notifications decreased at the time that the 
pan-American Health Organization registered the interruption of 
Triatoma infestans population in the area in 2006 (11); however, 
numbers still reached 1,539 new cases in the DATASUS from 
2007 to 2014. Nowadays, oral transmission of Chagas disease is 
the most frequent transmission route in the Brazilian Amazon 
region (12). Food/beverages contamination with T. cruzi-infected 
insect excreta, macerate, or reservoir meal is responsible for oral 
transmission in one to more than a hundred cases (outbreaks). 
It is noteworthy that oral transmission has been associated with 
high mortality and morbidity, including increased prevalence 
and severity of the cardiac pathology (myocarditis) (13–16). 
Argentina, Bolivia, Colombia, Ecuador, French Guiana, and 
Venezuela have also reported acute Chagas disease outbreaks 
associated with contaminated food consumption [revised in Ref. 
(11, 17)]. Fruits pasteurization is the appropriate pathway to kill 
the parasite, and it has been shown that outbreaks of oral infection 
in Brazilian Amazonia increase with seasonal months of higher 
açaí pulp production. Moreover, epidemiological data suggest 
that in the Pará state most of the cases are caused by consump-
tion of artisanal açaí. Therefore, good practices of quality control 
could avoid the transmission, such as good agricultural practice 
and “bleaching” or “whitening” of the fruits (12, 18).
The infection is presently considered as a worldwide health 
problem with deficiencies in treatment, absence of vaccines, and 
world spreading (19–22).
PARASiTe–HOST iNTeRACTiON AND 
TARGeT TiSSUeS
T. cruzi presents one of the most complex life cycles among the 
trypanosomatids, alternating between vertebrate hosts, which 
comprises a wide range of mammals including humans and 
invertebrate hematophagous insects from the Reduviidae fam-
ily (23, 24). Mammalian cell invasion by the T. cruzi is critical 
to its survival in the host. Once inside the vertebrate host, the 
metacyclic trypomastigotes are able to infect several nucleated 
mammalian cells at the inoculation site, such as macrophages, 
fibroblasts, epithelial cells, and others. The intracellular cycle in a 
mammalian cell presents different steps and begins at the moment 
that infective forms of T. cruzi interact with phagocytic or non-
phagocytic surface molecules. These processes lead to cell signal-
ing and internalization of the parasite through multiple endocytic 
pathways (25–27). T. cruzi proteins such as gp82, gp80, gp35/50, 
gp85, trans-sialidase, and host cell adhesion molecules such as 
mucins, VLA (very late antigen), and extracellular matrix pro-
teins (ECM) such as laminin and fibronectin have been reported 
to contribute to parasite infection (23, 25, 28–33). In addition, 
T. cruzi proteases as cruzipain, oligopeptidase B, and Tc80 have 
been implicated in T. cruzi internalization (23, 31). In addition 
to presenting a large variety of surface molecules that can par-
ticipate in host–parasite interaction, strain and forms (metacyclic 
trypomastigotes, tissue culture-derived trypomastigotes, and 
amastigotes) of the parasite differently express these molecules in 
the membrane. The capacity of trypomastigotes to interact with 
a diverse number of molecules on cell surface is determinant to 
improve invasion processes and allows the parasite to explore 
survival and multiplicative strategies in the host (23, 31, 34).
It is believed that any mammalian host cell class of molecules 
in the membrane are potential partners for T. cruzi recognition, 
and the expression of these molecules can vary depending on 
the cell type involved. Well-characterized groups of receptor 
are carbohydrates that contain galactosyl, mannosyl, and sialyl 
residues and lectin-like proteins (23, 26). Interestingly, T. cruzi is 
either able to use and increase expression of ECM in the host cell 
during the initial process of infection. Regarding T. cruzi surface 
molecules, it has been shown that trypomastigote forms present 
motifs that bind to cytokeratin 18, fibronectin, laminin, heparan 
sulfate proteoglycans, and integrins (35, 36).
The components involved in T. cruzi oral infection were 
suggested in experimental models. Hoft and colleagues demon-
strated by histological analysis that after oral infection, T. cruzi 
invades and replicates inside epithelial cells within the gastric 
mucosa. This initial invasion is followed by the establishment 
of a progressive gastritis and further systemic dissemination 
of the parasite. Furthermore, hypertrophy and the presence of 
parasites in adjacent lymph nodes of stomach and inflammatory 
infiltrates in various organs (pancreas, liver, spleen, bone marrow, 
heart, duodenum, adrenal, brain, and/or skeletal muscle) were 
also described. Amastigote nests were detected in the gastric 
mucosal epithelium, but not in the upper gastrointestinal tract, 
like esophagus and oropharynx after oral infection. These data 
suggested that oral infection initiates in gastric mucosal followed 
by systemic dissemination (37).
Analysis of molecular mechanisms involved in T. cruzi inter-
action with host cells during oral infection is under investigation. 
It has been suggested that gastric epithelium express mucins that 
interacts with T. cruzi glycoproteins, such as gp82 and gp30, trig-
gering a cascade of intracellular signaling in the parasite and at 
the host cell, leading to the mobilization of intracellular Ca2+ that 
is essential for parasite internalization (32, 34, 38, 39).
In line with this, previous studies of intrapharyngeal infec-
tion in mice, and in vitro studies of human epithelial cells have 
demonstrated the key role of glycoprotein gp82 during T. cruzi 
invasion in gastric of mucosal (40). Gp82 is present in metacyclic 
trypomastigotes forms, but not in amastigotes, epimastigotes, 
or tissue culture-derived trypomastigotes forms (41, 42). 
Interestingly, gp82 expressed in different T. cruzi strains is resist-
ant to degradation by pepsin or proteinase K (43, 44). Metacyclic 
forms of T. cruzi recovered from the stomach 1 h after an intrap-
haryngeal inoculation in mice preserve the gp82 intact, and the 
parasite infectivity was not altered. Furthermore, T. cruzi gp82−/− 
metacyclic forms have reduced gastric mucin-binding capacity, 
less efficient migration through the gastric mucin-coated and low 
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infectivity in mice by the intrapharyngeal route when compared 
with metacyclic forms that express gp82 (44, 45).
GP30 is another glycoprotein involved in T. cruzi interaction 
with the gastric epithelium, binding the target cells in a receptor-
dependent manner, inducing Ca2+ response and lysosome 
exocytosis, both required for the parasite internalization in the 
cell (44, 45). Interestingly, gp30 shows a lower affinity to gastric 
mucin-binding proteins as compared to gp82, and this seems to 
be associated with low infective capacity of gp82-deficient strains 
in vivo (45, 46). Different isolates of Y strain differ in the expres-
sion of gp82 and gp30 surface molecules and the ability to infect 
mice by the intragastric/intrapharyngeal inoculation (46).
The infection process is also influenced by gp90, a metacy-
clic stage-specific molecule, that binds to mammalian cells in 
receptor-dependent manner but, differently from gp82, this 
protein is unable to trigger Ca2+ signal and downmodulates the 
parasite cell invasion capacity (47). It has been shown that T. cruzi 
strains that express high levels of gp90 on the surface, in addition 
to gp82 and gp30, have low cellular infection capacity in vitro. 
However, recent in  vivo studies indicated that infectivity of 
T. cruzi is also influenced by the susceptibility of g90 molecules to 
peptic digestion. T. cruzi strains expressing pepsin-resistant gp90 
isoform show a low capacity to invade gastric mucosal epithelium 
after intrapharyngeal inoculation in mice, resulting in subpat-
ent or low parasitemia. By contrast, T. cruzi strains expressing 
pepsin-susceptible gp90 produced high parasitemia and high 
mortality when given to mice by the intrapharyngeal route (43). 
In addition, analysis of extracellular vesicles and soluble proteins 
released by metacyclic trypomastigotes forms of T. cruzi has 
revealed presence of gp82 and gp90 surface molecules in these 
compartments (48, 49).
A variety number of molecules involved in parasite–host cell 
interactions are potential candidates in oral infection. During the 
oral infection, parasites come across different cells throughout 
the gastrointestinal tract, from tissues as the mouth to intestines. 
In previous data, Diaz-Ungría and Bracho showed signs of a 
possible T. cruzi penetration in the oral, esophageal, gastric, and 
intestinal mucosa with local eosinophilia, infiltrated lymphocytes 
and monocytes in histological sections from dogs after oral infec-
tion (50). We have recently demonstrated that the site of parasite 
entrance, through the mouth (oral infection—OI), which is more 
similar to natural infection, versus gastrointestinal infection (GI) 
promotes different host immune response and mortality. Thus, 
compared with GI mice, OI mice presented elevated infection rate, 
parasitemia, and higher Th1 cytokines (51) (Figures 1A,B). This 
distinct immunological response and infection severity accord-
ing to the different mucosal pathways highlighted important 
considerations concerning the primary site of T. cruzi infection 
in the oral route and indicated that the pathophysiology in this 
model may not be the same when parasites are administrated into 
the oral cavity or by gavage into the stomach (intrapharyngeal/
intragastric).
In a recent study, the site of parasite entry in OI mice, 
inoculating T. cruzi directly in the mouth and analyzing by 
bioluminescence imaging corroborates the hypothesis that oral 
cavity is a potential critical site of initial T. cruzi infection before 
spreading to other organs in the acute phase. Moreover, OI leads 
to T. cruzi entrance in the palate, multiplication at the nasal cav-
ity and dissemination to central nervous system and peripheral 
tissues. These evidences suggest that oral cavity is the primary site 
of infection and the nasal cavity comprises most of the parasite 
replication (52) (Figures 1C,D). Interestingly, facial edema and 
paresthesia of the tongue were already described in patients 
infected with T. cruzi by the oral route (53).
The mouth/oral cavity is also a target tissue for different viral, 
bacterial, and fungal infections disease, such as Herpes virus type 
1 and 2, Helicobacter pylori, Candida albicans, and others disease 
(54–56). The oral cavity contains distinct mucosal surfaces and 
molecules expression, such as mucins, in which microorganisms 
can bind and, consequently colonize this anatomical region (57). 
The oral mucosa is coated by a film of mucus consisting of lipids, 
glycosylated proteins, such as mucin immunoglobulins, as well as 
growth factors and others. The mucins are considered as the first 
line of defense in the oral cavity, preventing the attachment of 
certain pathogens to the epithelium or forming aggregates facili-
tating the elimination of pathogens by the organism. However, 
some pathogens can bind in the carbohydrate structures present 
in the mucins, such as sialic acids, which favors access to epithelial 
cells and cell invasion (57–59).
Previous data demonstrated that Streptococcus sp. binds to sali-
vary mucins on the surface of the tooth, being one of the first steps 
in the formation of dental plaque (60). Studies using Tannerella 
forsythia, one of the major bacterial pathogens associated with 
periodontitis, uncovered that glycoprotein-associated sialic acid 
in terminal sugars on the surface of oral cavity epithelium is 
important for the adhesion and invasion of these bacteria. In this 
study, parasite inactivation by mutation or inhibition of NanH 
sialidase decreased the adhesion and invasion of T. forsythia in 
human gingival epithelial cell culture lines (OBA-9). The NanH 
sialidase activity is specific for α-2,3 sialic acid present on the 
surface of gingival epithelial cells, suggesting its role in parasite 
adhesion and invasion (61, 62).
In line with these findings, Lakdawala and colleagues demon-
strated that the soft palate is a relevant focus of influenza viruses’ 
infection. The soft palate is a mucin-rich environment, which 
favors the infection and may contribute to airborne transmission. 
Furthermore, the expression of α-2,3 sialic acids, the viral hemag-
glutinin ligands, is detected on the soft palate, in the regions of 
the oral surface and the nasopharyngeal tissues from humans and 
ferret (63).
Interestingly, α-2,3 sialic acids are the main molecule involved 
in T. cruzi trans-sialidase-mediated binding. Trans-sialidase are 
considered as an important virulence factor, since this enzyme 
is able to reduce host cell immune response and mediates 
T. cruzi and host cells adhesion (33). It has been shown that 
trans-sialidase binds to host sialoglycans, generating “eat me” 
signals in epithelial cells, which facilitates parasite entry into non-
phagocytic cells (64). Notably, the mouth seems to be a potential 
source of infection and this knowledge contributes to the eluci-
dation of the target tissue/organs and the molecular components 
regulating the establishment of T. cruzi oral infection and its 
pathogenesis.
FiGURe 1 | Continued
4
Barreto de Albuquerque et al. Disease/Immunity in Mucosal Infection
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1734
FiGURe 1 | Severity and target tissues during acute phase of Trypanosoma cruzi orally infected mice. (A) Male BALB/c mice were infected with 5 × 104 tissue 
culture-derived trypomastigotes forms of T. cruzi (Tulahuén strain) through gavage [gastrointestinal infection (GI)] or oral cavity (OI). Parasitemia (mean and SEM) was 
assessed during the acute phase and expressed as ln parasites per milliliter for statistical analysis. Parasites were counted by light microscopy, and parasitemia 
calculated by the Brenner method. Parasitemia comparisons were performed at different days post-infection (dpi), Kruskal–Wallis, Dunn’s post-test (until 15 dpi), 
and one-tailed Mann–Whitney (after 15 dpi) tests were used. (A) n: GI, 3 dpi = 7; 7 dpi = 22; 9 dpi = 29; 12 dpi = 17; 15 dpi = 45; 17 dpi = 10; 21 dpi = 24; 
25 dpi = 16; 29 dpi = 11 and OI, 3 dpi = 4; 7 dpi = 9; 9 dpi = 14; 12 dpi = 22; 15 dpi = 40; 17 dpi = 12; 21 dpi = 14; 25 dpi = 8; 29 dpi = 6. Lower numbers 
represent early stages, when parasitemia was still undetectable and final stages, when mortality rates were too high. (B) Cytokine analysis in GI and OI mice. Male 
BALB/c mice were infected with 5 × 104 tissue culture-derived trypomastigotes forms of T. cruzi (Tulahuén strain) through gavage (GI) or within oral cavity (OI). In the 
course of acute infection, serum was isolated and levels of cytokines (IFN-γ, TNF, IL-17, IL-10, and TGF-β) were quantified in uninfected control and infected mice 
by a multiplex analysis. The results are expressed as the mean values (±SEM) for each group/day post-infection. n: IFN-γ, uninfected (0) = 12; 3 dpi GI = 11, 
OI = 5; 9 dpi GI = 8, OI = 5; 12 dpi GI = 9, OI = 4; 17 dpi GI = 4, OI = 6. TNF, uninfected (0) = 11; 3 dpi GI = 10, OI = 10; 9, 12 dpi, GI = 3, OI = 3; 17 dpi, GI = 6, 
OI = 11. IL-17, uninfected (0) = 12; 3 dpi, GI = 10, OI = 10; 9 dpi, GI = 3, OI = 3; 12 dpi, GI = 5, OI = 5; 17 dpi, GI = 6, OI = 14. TGF-β, uninfected (0) = 6; 3 dpi, 
GI = 4, OI = 4; 9 dpi, GI = 5, OI = 5; 12 dpi, GI = 5, OI = 4; 17 dpi, GI = 2, OI = 5. IL-10 and IL-4, uninfected (0) = 6; 3, 9, 12 dpi, GI = 6, OI = 6; 17 dpi, GI = 3, 
OI = 8. Statistical analysis was performed using GraphPad Prism 5. *p = 0.05; **p = 0.01; ***p = 0.001. (C) Course of parasite distribution in oral infection. Male 
BALB/c mice were infected in the oral cavity (OI) with 1 × 106 trypomastigotes forms of T. cruzi expressing luciferase (Dm28c-luc). Representative in vivo 
bioluminescence images were acquired in the same mice (n = 6), at 7 and 21 dpi, after 15 min of d-luciferin intraperitoneal administration (150 mg/kg), using IVIS® 
Lumina image system (Xenogen). (D) T. cruzi loads in orally infected mice. Male BALB/c mice were infected in the oral cavity (OI) with 1 × 106 trypomastigotes forms 
of T. cruzi expressing luciferase (Dm28c-luc). Organs and tissues were harvested for qPCR analysis to determine the parasite load (parasite equivalent/g) at 60 min, 
7, and 21 dpi. The qPCR was performed in multiplex, targeting T. cruzi nuclear satellite DNA (Sat DNA) and IAC (internal amplification control), as a quality control. 
Parasite load in the nasal cavity (n: 60 min and 7 dpi = 5; 21 dpi = 4), esophagus (n: 60 min = 4; 21 dpi = 3), stomach (n: 60 min and 7 dpi = 4; 21 dpi = 3), small 
intestine (n: 60 min = 5; 7 dpi = 3; 21 dpi = 4), large intestine (n: 60 min = 5; 7 and 21 dpi = 4), and mandibular lymph nodes (n: 60 min = 4; 7 and 21 dpi = 3). 
Red dots: no parasite detection. Values present mean ± SEM. Kruskal–Wallis (Dunn’s post-test) for group kinetics. Statistical analysis was performed using Graph 
Pad Prism 5. *p < 0.05, **p < 0.01. Adapted from Barreto-de-Albuquerque et al. (51) and Silva-dos Santos et al. (52).
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iMMUNe ReSPONSe AND DiSeASe 
OUTCOMe iN eXPeRiMeNTAL MODeLS
The most widely used experimental model to study T. cruzi 
infection has been for years the intraperitoneal (IP) inoculation 
of the parasite in mice, in which 102 trypomastigotes are able 
to promote functional alterations in the immune system from 
14 days post-infection (dpi) (65). However, this pathway does not 
mimic the natural infection through contaminated excreta left 
by the vector after biting. More importantly, especially in Brazil 
and other endemic countries, the most frequent transmission 
route has been reported to be by ingestion of contaminated food 
and beverages (7, 17, 66, 67). Several approaches to address oral 
infection in mice have been described in the literature, such as 
intrapharyngeal, intragastric, and in the oral cavity inoculation 
(37, 44, 45, 51, 68–70).
Comparing mucosal routes through the digestive tube with 
systemic inoculation, differences in disease outcome and immune 
response can be observed. Intraperitoneally infected mice present 
higher parasitemia and mortality than intragastric or oral cavity-
inoculated mice with the same inoculum (51, 69, 71). Besides, 
IP-infected mice also start to die earlier than GI/OI-infected 
and present 80–100% mortality, while GI/OI results in higher 
survival rates. Still, OI leads to parasitemia and mortality levels 
higher than in GI models. Infection through gavage (intragastri-
cally) presents less percentage of mice with patent parasitemia, 
parasitemia, and mortality than IP injection (51, 70). Despite 
intermediate parasitemia and mortality levels between GI and IP, 
OI infection leads to a percentage of mice with patent parasitemia 
similar to IP (49.3% for GI and 97.5% for OI) (51). These temporal 
and quantitative differences in parasitemia might be related to the 
distinct barriers the parasite needs to cross after these inocula-
tion routes. As it has been discussed in the literature, the route of 
parasite inoculation affects the pathogenesis and disease outcome 
of experimental T. cruzi infection (72).
After oral infection, parasites have been detected in several 
tissues, and even where they are not detected, inflammatory 
infiltrates are found (37, 52). Systemic versus mucosal T. cruzi 
infection leads to distinct disease patterns. Systemic infec-
tions with Peruvian strain, such as IP, IV (intravenous), or SC 
(subcutaneous) promote higher infection rates (67–100%) and 
mortality than mucosal, such as OI, GI, intrarectal, genitalia, or 
conjunctival infection (17–67%) (73). By contrast, the study by 
Caradonna and Pereiraperrin (74), mice infected with Tulahuén 
strain through intranasal (IN) route present higher mortality 
than SC. In addition, after an oral inoculation (oropharynx), 
insect-derived metacyclic trypomastigotes are more infective 
when compared to cutaneous challenge (over puncture wound 
that is not the same as the SC) (75).
Inoculation route can also lead to preferential tropism, as well 
as distinct local and systemic immune responses (51, 52, 72, 74) 
(Table 1). Inflammatory infiltrates can be found in the heart and 
the severity is not necessarily the main cause of death (37, 51, 
69). Infiltration of immune cells is observed in several organs 
regardless the presence of parasite (37). The literature shows 
that Tulahuén strain of T. cruzi induces TNF production and 
apoptosis of hepatocytes (76). In this regard, OI and GI infection 
leads to apoptosis in the liver and in the heart of acute infected 
mice and the macrophages are the main source of TNF. These 
different pathways can also lead to elevated serum IFN-γ levels 
and TNF, especially in OI (51). Also in the heart higher levels 
of TNF mRNA is detected in OI when compared with GI. This 
elevated TNF levels in OI may be associated with cardiac, spleen, 
and hepatic damage, as well as toxic shock in mice, as reported 
in studies with other models (51, 77, 78). Besides, it can be con-
sidered one of the factors for death in mice, since blockage of this 
cytokine improves the survival (51).
After OI or GI, different cell types can be found within the heart 
and liver, such as CD4+ and CD8+ cells, neutrophils, and mac-
rophages. Among them, macrophages constitute the main source 
TABLe 1 | Cytokines are differentially expressed according to the infection route.
Gi Reference Oi Reference
CCL3 ↑ stomach (a; c)/spleen (c) (79) N.A. –
CCL5 ↑ stomach (c)/heart (c) (79) N.A. –
CXCL1 ↑ stomach (c)/heart (c) (79) N.A. –
CXCL10 ↑ stomach (c)/heart (c)/
spleen (c)
(79) N.A. –
CXCL9 ↑ stomach (c)/heart (c)/
spleen (c)
(79) N.A. –
G-CSF ↑ stomach (c) (79) N.A. –
IFN-γ ↑ stomach (a; c)/spleen (c)/
serum (a)
(51, 79) ↑ IEL (a)/
LP (a)/↑↑ 
serum (a)
(37, 51)
IL-10 ↑ stomach (a; c)/heart (c)/
spleen (a)
(79) ↑ serum 
(a)
(51)
IL-12 ↑ stomach (a; c)/heart (c)/
spleen (a)
(79) N.A.
IL-17 ↑ serum (a) (51, 79) ↑↑ serum 
(a)
(51)
IL-2 ↑ stomach (c)/spleen (c) (79) N.A. –
IL-3 ↑ stomach (a; c) (79) N.A. –
IL-4 ↑ stomach (a; c)/spleen (c) (79) ↑ serum 
(a)
(51)
IL-6 ↑ spleen (c) (79) N.A. –
IL-7 ↑ stomach (c)/spleen (c) (79) N.A. –
IL-9 ↑ spleen (c) (79) N.A. –
M-CSF ↑ stomach (c) (79) N.A. –
TGF-β ↑↑ serum (a) (51) ↑ serum 
(a)
(51)
TNF ↑ stomach (c)/spleen (c)/liver 
(a)/heart (a)/↑ serum (a)
(51, 79) ↑ liver/
heart/↑↑ 
serum (a)
(51)
GM-CSF ↑ spleen (a; c) (79) N.A. –
GI, gastrointestinal infection; OI, oral infection; a, acute phase; c, chronic phase; N.A., 
not analyzed; IEL, intraephitelial lymphocytes; LP, lamina propria.
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of tissue TNF (51). In acute and chronic phase, inflammation can 
be detected in the stomach and heart after GI infection, followed 
by alterations in cytokine production. An increase of IL-12, 
IFN-γ, IL-4, IL-10, CCL3/4, and IL-3 is observed in the stomach 
during the acute phase of the disease and IL-12, TNF-α, CCL3/4, 
CXCL1, CCL5, CXCL9, CXCL10, G-CSF, M-CSF, IL-2, and IL-7 in 
the chronic phase. Hoft and collaborators demonstrated that after 
oral inoculation, T. cruzi infection within the gastric epithelium 
is able to stimulate B cell responses with parasite-specific IgA and 
IgG, suggesting activation of these cells in mucosal inductive sites, 
such as Peyer’s patches, although the presence of parasite was not 
proven there. Furthermore, gastric intraepithelial lymphocytes 
and from lamina propria produce IFN-γ (37). In the heart, IL-10 
and CXCL1 increase in animals GI-infected with the CL strain, in 
addition to IL-12, IL-10, CXCL9, and CXCL10 during the chronic 
phase. Of note, this profile can vary according to strain (79). Yet, 
little is known after oral inoculation of the parasite.
It was already described after IP infection, alterations in 
secondary lymphoid organs are observed in acute infection with 
an increase in total cell numbers and individual subsets as well as 
cytokine production in the subcutaneous lymph nodes and spleen, 
and a decrease in mesenteric lymph nodes and thymus (65, 80). 
After GI, there is an increase of neutrophils, lymphocytes, and 
monocytes and a reduction of the number of eosinophils in 
GI- and IP-infected mice. As demonstrated in Domingues and 
colleagues study, the peak of parasitemia in GI at 18 dpi is cor-
related with an increase in monocytes in the blood. The spleen 
also increases in GI, mainly CD8+ cells and double-positive 
CD8+CD4+, but at a later time and the thymus is slightly increased 
instead of the atrophy observed after IP (70). High levels of IL-12, 
IL-10, and GM-CSF are expressed in the spleen during the acute 
phase of CL strain-infected mice, while IFN-γ, TNF-α, IL-6, IL-4, 
IL-9, CCL3/4, CXCL9, CXCL10, GM-CSF, IL-2, and IL-7 are 
elevated during chronic infection (79). The mesenteric lymph 
nodes decrease in GI with reduction of CD4+ cells (70). Of note, 
the only study addressing lymphoid organ alteration after oral 
infection (oral cavity inoculation) reports an increase of gastric 
lymph nodes (37).
Regarding systemic cytokines GI and OI mice have a high con-
centration of serum IL-4, while OI leads to lower amounts of the 
regulatory cytokine IL-10 and TGF-β. These cytokines are known 
to inhibit macrophage microbicidal function, protecting the host 
from tissue damage (77, 81). Furthermore, inoculation of parasite 
through digestive mucosa (oral and more in GI) triggers IL-17 
production, which is reflected in the serum. IL-17-producing 
cells have also been described to contribute to the formation of 
the gastrointestinal barrier (82). Moreover, mucosal infections 
(IN or OI/GI) with bacteria, such as Listeria monocytogenes 
(Lm), Streptococcus pyogenes, and Francisella tularensis leads to 
Th17 responses, while the systemic routes (IV or SC) trigger a 
Th1 response (83).
For different infection models systemic inoculations, IP, IV, 
and SC have been widely used. Although these approaches do 
not always necessarily mimic the natural transmission pathway. 
Our group and others have already demonstrated that the route 
of parasite administration is relevant for the disease outcome 
in infections by different pathogens (72, 84). Besides as ideal 
experimental model should mimic all phases of infection, includ-
ing the transmission pathway (84). In this regard, for food-borne 
diseases, oral inoculation is an essential issue to consider.
Considering the human counterpart in Chagas disease, oral 
transmission has become more epidemiologically relevant and 
the outbreaks are related to contaminated food ingestion (85). 
Interestingly, facial edema is frequently observed in these patients 
(53). In experimental models, we described that host response is 
distinct when parasites are delivered into the oral cavity or by gav-
age (51). As it has been discussed also in non-infectious models, 
the oral cavity represents the first contact with the organism after 
ingestion and presents an underexplored environment. Thus, it 
should really be considered as more than just the entrance for 
the gastrointestinal tract (86). Tolerogenic dendritic cells produc-
ing IL-10 and IL-12 (regulatory and inflammatory profiles) can 
capture parasite/antigens within the mucosa in the oral cavity and 
in the gastrointestinal tract from where they can also be drained 
to the liver by the portal system (87, 88). Thus, regarding oral 
infections, parasite delivery into the oral cavity or by gavage 
(intrapharyngeal/gastrointestinal) should not be assumed as 
equivalent processes.
The importance to standardize the nomenclature and the 
choice among different approaches to address “oral” infection, 
such as ad  libitum, oral gavage and in the oral cavity has been 
discussed also in the context of other food-borne diseases, such 
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as Listeriosis, caused by the bacteria Lm (84). After GI Lm 
inoculation, high amounts of Lm and specific T cells are found 
in the intestinal mucosa, mesenteric lymph nodes, spleen, and 
liver, whereas ingestion of Lm-contaminated bread promotes 
increased and phenotypically distinct intestinal resident memory 
cells (TRM) compared with other routes of infection (89–91). 
Moreover, IV and IN routes are able to induce TH1 and TH17 
CD4+ cells, respectively, but TH1 cells from IV were are more 
likely to originate a memory cell pool than TH17 from IN (92).
CONCLUSiON AND PeRSPeCTiveS
Nowadays, T. cruzi oral transmission is an important route of 
infection in Latin American countries. Despite its relevance, sig-
nificant studies about this form of parasite infection are largely 
lacking. Experimental studies related to oral T. cruzi and other 
infective agents usually comprise inoculation in the mouth (OI) 
or intragastrically/intrapharyngeal (GI), being roughly consid-
ered as similar routes of infection. In this review, we unraveled the 
intrinsic importance of specific (and distinct) tissues involved 
in the primary site of an infective agent entrance, resulting in 
regional immune response and differential disease outcome. 
New studies investigating the influence of target tissues and 
host–parasite interactions in OI and GI must be performed.
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